Abbott Laboratories (ABT) : Courier Capital Corp scooped up 125 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 28,944 shares of Abbott Laboratories which is valued at $1,301,033.Abbott Laboratories makes up approximately 0.25% of Courier Capital Corp’s portfolio.
Other Hedge Funds, Including , Channing Capital Management boosted its stake in ABT in the latest quarter, The investment management firm added 30,622 additional shares and now holds a total of 181,489 shares of Abbott Laboratories which is valued at $8,157,931. Abbott Laboratories makes up approx 0.33% of Channing Capital Management’s portfolio.Redwood Investments reduced its stake in ABT by selling 38 shares or 27.14% in the most recent quarter. The Hedge Fund company now holds 102 shares of ABT which is valued at $4,454.Tokio Marine Asset Management Co Ltd reduced its stake in ABT by selling 1,793 shares or 4.3% in the most recent quarter. The Hedge Fund company now holds 39,869 shares of ABT which is valued at $1,741,079. Abbott Laboratories makes up approx 0.17% of Tokio Marine Asset Management Co Ltd’s portfolio. K.j. Harrison Partners Inc sold out all of its stake in ABT during the most recent quarter. The investment firm sold 5,000 shares of ABT which is valued $218,350.Piershale Financial Group boosted its stake in ABT in the latest quarter, The investment management firm added 2 additional shares and now holds a total of 384 shares of Abbott Laboratories which is valued at $16,163. Abbott Laboratories makes up approx 0.01% of Piershale Financial Group’s portfolio.
Abbott Laboratories closed down -0.14 points or -0.31% at $44.81 with 65,83,457 shares getting traded on Thursday. Post opening the session at $45.06, the shares hit an intraday low of $44.78 and an intraday high of $45.09 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.